Proposal for priority regulatory review of Canadian-made drugs to incentivize domestic production and ensure supply chain resilience.

Proposal for formulary exclusivity and regulatory amendments to prioritize Canadian-made pharmaceuticals and strengthen domestic production.

CPMEA provides input on the Buy Canadian Policy: federal procurement strategies to prioritize Canadian-made pharmaceuticals, investment, and supply chain resilience.

CPMEA calls for a ‘Canada First’ regulatory path to safeguard Canadian pharmaceutical production and supply.

CPMEA submission to Health Ministers advocating for Canada-first pharmaceutical policies, domestic manufacturing incentives, and national supply security.

CPMEA submission to the 2025 CUSMA review on tariffs, IP protections, and market access for Canadian pharmaceutical exports.

CPMEA comments to the 2025 federal budget consultation on pharmaceutical manufacturing, Canada-first procurement, national security, and drug supply resilience.

CPMEA submission to the U.S. Department of Commerce on the Section 232 investigation, urging exemptions for Canadian pharmaceuticals and highlighting their role in U.S. national security.

CPMEA comments on U.S. tariffs, generic drug shortages, trade barriers, and North American pharmaceutical supply chains.

CPMEA submission to Health Canada on proposed drug shortage regulations, warning of impacts on domestic pharmaceutical manufacturing, supply security, and access to medicines.

Review of CUSMA, highlighting pharmaceutical trade, regulatory alignment, and secure access to U.S. and Mexico markets.

Submission on PHAC Science Strategy, emphasizing domestic manufacturing as essential for public health resilience and drug supply security.

CPMEA comments on SR&ED tax credits and their role in incentivizing pharmaceutical R&D and domestic manufacturing.

CPMEA submission to Health Canada outlining regulatory concerns and solutions to address drug shortages in Canada.